The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Protection against cognitive deficits and markers of neurodegeneration by long‐term oral administration of melatonin in a transgenic model of Alzheimer disease
Abstract
Abstract: The neurohormone melatonin has been reported to exert anti‐β‐amyloid aggregation, antioxidant, and anti‐inflammatory actions in various in vitro and animal models. To comprehensively determine the potential for long‐term melatonin treatment to protect Alzheimer’s transgenic mice against cognitive impairment and development of β‐amyloid (Aβ) neuropathology, we administered melatonin (100 mg/L drinking water) to APP + PS1 double transgenic (Tg) mice from 2–2.5 months of age to their killing at age 7.5 months. A comprehensive behavioral battery administered during the final 6 weeks of treatment revealed that Tg mice given melatonin were protected from cognitive impairment in a variety of tasks of working memory, spatial reference learning/memory, and basic mnemonic function; Tg control mice remained impaired in all of these cognitive tasks/domains. Immunoreactive Aβ deposition was significantly reduced in hippocampus (43%) and entorhinal cortex (37%) of melatonin‐treated Tg mice. Although soluble and oligomeric forms of Aβ1‐40 and 1‐42 were unchanged in the hippocampus and cortex of the same melatonin‐treated Tg mice, their plasma Aβ levels were elevated. These Aβ results, together with our concurrent demonstration that melatonin suppresses Aβ aggregation in brain homogenates, are consistent with a melatonin‐facilitated removal of Aβ from the brain. Inflammatory cytokines such as tumor necrosis factor (TNF)‐α were decreased in hippocampus (but not plasma) of Tg+ melatonin mice. Finally, the cortical mRNA expression of three antioxidant enzymes (SOD‐1, glutathione peroxidase, and catalase) was significantly reduced to non‐Tg levels by long‐term melatonin treatment in Tg mice. Thus, melatonin’s cognitive benefits could involve its anti‐Aβ aggregation, anti‐inflammatory, and/or antioxidant properties. Our findings provide support for long‐term melatonin therapy as a primary or complementary strategy for abating the progression of Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Tan, D., Manchester, L. C., Terron, M. P., Flores, L. J., & Reiter, R. J. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00407.x · Cited by 1,601
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Tan, D.-X., Reiter, R., Manchester, L., Yan, M.-T., El-Sawi, M., Sainz, R., Mayo, J., Kohen, R., Allegra, M., & Hardelan, R. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023394443 · Cited by 1,065
Praticò, D., Uryu, K., Leight, S., Trojanoswki, J. Q., & Lee, V. M.-Y. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04183.2001 · Cited by 777
Arendt, J., & Skene, D. J. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2004.05.002 · Cited by 629
Human pineal physiology and functional significance of melatonin
Macchi, M. M., & Bruce, J. N. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.08.001 · Cited by 547
Melatonin-Immune System Relationships
Guerrero, J., & Reiter, R. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023394335 · Cited by 475
Carrillo‐Vico, A., Calvo, J. R., Abreu, P., Lardone, P. J., García‐Mauriño, S., Reiter, R. J., & Guerrero, J. M. (2004) · The FASEB Journal · doi:10.1096/fj.03-0694fje · Cited by 458
Cited by
Galano, A., Tan, D. X., & Reiter, R. J. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00916.x · Cited by 1,146
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Melatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Melatonin: Buffering the Immune System
Carrillo-Vico, A., Lardone, P., Álvarez-Sánchez, N., Rodríguez-Rodríguez, A., & Guerrero, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048638 · Cited by 740
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Metadata
- Authors
- Olcese, J. M., Cao, C., Mori, T., Mamcarz, M. B., Maxwell, A., Runfeldt, M. J., Wang, L., Zhang, C., Lin, X., Zhang, G., & Arendash, G. W.
- Venue
- Journal of Pineal Research
- Publisher
- Wiley
- Published
- 2009-07
- Volume
- 47
- Issue
- 1
- Pages
- 82-96
- ISSN
- 0742-3098 (ISSN-L)
- 1600-079X
- OpenAlex
- W2155856211
- Cited by
- 260
- References
- 64
- FWCI
- 16.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protection against cognitive deficits and markers of neurodegeneration by long‐term oral administration of melatonin in a transgenic model of Alzheimer disease. https://app.cochat.ai/papers/10.1111/j.1600-079x.2009.00692.x
- The paper
- Olcese, J. M., Cao, C., Mori, T., Mamcarz, M. B., Maxwell, A., Runfeldt, M. J., Wang, L., Zhang, C., Lin, X., Zhang, G., & Arendash, G. W. (2009). Protection against cognitive deficits and markers of neurodegeneration by long‐term oral administration of melatonin in a transgenic model of Alzheimer disease. Journal of Pineal Research. https://doi.org/10.1111/j.1600-079x.2009.00692.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.